Vestibular schwannoma (VS) is a benign tumor that typically develops on the vestibulocochlear nerve, affecting hearing and balance. The disease accounts for approximately 6% of all intracranial tumors, with an estimated incidence of 3-5 per 100,000 individuals. There is a high unmet clinical need for better therapies to treat the disease, as current treatment options, such as surgery and radiation, often come with significant risks and side effects. Further, the growing focus on precision medicine and novel therapeutic approaches is likely to support pipeline growth in the coming years, offering hope for more effective and less invasive treatments.
The Vestibular schwannoma Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into vestibular schwannoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vestibular schwannoma. The vestibular schwannoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The vestibular schwannoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vestibular schwannoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vestibular schwannoma.
Vestibular schwannoma, also known as acoustic neuroma, is a benign tumor that develops on the vestibulocochlear nerve, which controls balance and hearing. This condition occurs when Schwann cells, responsible for producing the nerve's myelin sheath, grow abnormally. It typically affects adults and may cause symptoms like hearing loss, tinnitus, and balance issues. The tumor grows slowly and can compress adjacent brain structures, potentially leading to more severe complications.
Vestibular schwannoma treatment depends on tumor size, symptoms, and location. Options include observation for small tumors, surgical removal, and radiosurgery. Surgery aims to preserve hearing and facial nerve function while removing the tumor. Radiosurgery is a non-invasive alternative, particularly for smaller tumors. Early diagnosis and tailored treatment plans can help manage symptoms and reduce the risk of long-term complications.
A 2024 study found that the global incidence of vestibular schwannoma (VS) is 3–5 per 100,000 person-years. A 2023 study indicated that in the U.S., the incidence is 1.1 per 100,000 person-years, whereas Denmark reports a higher rate of 2.0 per 100,000. The condition is frequently associated with genetic factors and perinatal brain injuries. Regional prevalence varies, with higher rates observed in areas with advanced diagnostic capabilities and improved healthcare access.
This section of the report covers the analysis of vestibular schwannoma drug candidates based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total vestibular schwannoma clinical trials.
The drug molecule categories covered under the vestibular schwannoma pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vestibular schwannoma.
The EMR report for the vestibular schwannoma report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Vestibular Schwannoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vestibular schwannoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vestibular schwannoma drug candidates.
The study, sponsored by the Massachusetts Eye and Ear Infirmary, aims to evaluate the effects of aspirin on slowing tumor growth and maintaining or improving hearing in patients with vestibular schwannoma. This Phase II, randomized, double-blind trial is expected to be completed by February 2029, enrolling approximately 300 participants. The objective is to assess whether aspirin can delay progression in these patients.
Sponsored by the University of Alabama at Birmingham, this Phase 2 clinical trial investigates the efficacy of crizotinib in children and adults with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannomas. The study, expected to be concluded by December 2025, aims to enroll 19 participants and will assess clinical response using MRI volumetrics and audiology.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Vestibular schwannoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vestibular schwannoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vestibular schwannoma pipeline insights.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share